Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 504

The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.

Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus

Open access
Ferguson, Daniel, Finck, Brian N.·2021·Nature Reviews Endocrinology

Abstract

Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease in the world, yet there are still no approved pharmacological therapies to prevent or treat this condition. NAFLD encompasses a spectrum of severity, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). Although NASH is linked to an increased risk of hepatocellular carcinoma and cirrhosis and has now become the leading cause of liver failure-related transplantation, the majority of patients with NASH will ultimately die as a result of complications of type 2 diabetes mellitus (T2DM) and cardiometabolic diseases. Importantly, NAFLD is closely linked to obesity and tightly interrelated with insulin resistance and T2DM. Thus, targeting these interconnected conditions and taking a holistic attitude to the treatment of metabolic disease could prove to be a very beneficial approach. This Review will explore the latest relevant literature and discuss the ongoing therapeutic options for NAFLD focused on targeting intermediary metabolism, insulin resistance and T2DM to remedy the global health burden of these diseases. Type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are closely linked; effective therapeutics are lacking for both conditions, particularly NAFLD. This Review will discuss therapeutic options for NAFLD, focusing on targeting intermediary metabolism, insulin resistance and T2DM. Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease globally, yet there are currently no approved therapies. While NAFLD progression to non-alcoholic steatohepatitis is becoming the leading cause of end-stage liver failure, the leading causes of death in patients with NAFLD are complications of cardiometabolic disease. A tight relationship exists between NAFLD, insulin resistance and type 2 diabetes mellitus. It is likely that developing therapeutics that target both NAFLD and cardiometabolic risk factors might be extremely beneficial. Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease globally, yet there are currently no approved therapies. While NAFLD progression to non-alcoholic steatohepatitis is becoming the leading cause of end-stage liver failure, the leading causes of death in patients with NAFLD are complications of cardiometabolic disease. A tight relationship exists between NAFLD, insulin resistance and type 2 diabetes mellitus. It is likely that developing therapeutics that target both NAFLD and cardiometabolic risk factors might be extremely beneficial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41574-021-00507-z

Cites

164 of 164 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 164 references

Cited by

See all 504

Metadata

Authors
Ferguson, D., & Finck, B. N.
Venue
Nature Reviews Endocrinology
Published
2021-06-15
Volume
17
Issue
8
Pages
484-495
ISSN
  • 1759-5029 (ISSN-L)
  • 1759-5037
OpenAlex
W3170394737
Cited by
504
References
164
FWCI
17.05
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1038/s41574-021-00507-z
The paper
Ferguson, D., & Finck, B. N. (2021). Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-021-00507-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.